Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model

Autor:	David J. Rieman, William F. Huffaman, Kevin L. Salyers, Richard M. Keenan, Michael W. Lark, Janice A. Vasko-Moser, Thomas W. Ku, Maxine Gowen, Leonard M. Azzarano, Karl F. Erhard, Stephen T. Ross, Denise Zembryki, Bradbeer Jeremy N, Bondinell William E, Shing-Mei Hwang, William H. Miller, Kenneth A. Newlander, George B. Stroup, Beata Lechowska, Fred H. Drake, Keith W. Ward, Kyung O. Johanson, Brian R. Smith, Paula C. Adams, Ian E. James, R. Curtis Haltiwanger, Russell D. Cousins, Dalia R. Jakas, Sandra J. Hoffman
Rok vydání:	1999
Předmět:	Time Factors Clinical Biochemistry Integrin Administration Oral Aminopyridines Biological Availability Pharmaceutical Science Acetates Pharmacology Biochemistry In vivo Oral administration Drug Discovery Animals Receptors Vitronectin Molecular Biology Benzodiazepinones biology Chemistry Organic Chemistry Antagonist Biological activity Rats Bioavailability Disease Models Animal Kinetics biology.protein Ovariectomized rat Osteoporosis Molecular Medicine Vitronectin
Zdroj:	Bioorganic & Medicinal Chemistry Letters. 9:1807-1812
ISSN:	0960-894X
DOI:	10.1016/s0960-894x(99)00283-8
Popis:	A new series of potent nonpeptide vitronectin receptor antagonists, based on a novel carbocyclic Gly-Asp mimetic, has been discovered. A representative of this series, SB 265123 (4), has 100% oral bioavailability in rats, and is orally active in vivo in the ovariectomized rat model of osteoporosis.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49bebe15e69e0b6c6398f79a6e04504c https://doi.org/10.1016/s0960-894x(99)00283-8 Zobrazit plný text záznamu Full Text from ScienceDirect